| Tpl2 may serve more as a tumor suppressor than as an oncogene in chemically induced skin carcinogenesis. | skin, |
| Tpl2, a potent oncogene, functions as a tumor suppressor gene in chronically stimulated T cells. | None |
| Tpl2 may serve more as a tumor suppressor than as an oncogene in chemically induced skin carcinogenesis. | skin, |
| Oncoprotein Cot1 represses kinase suppressors of Ras1/2 and 1,25-dihydroxyvitamin D3-induced differentiation of human acute myeloid leukemia cells. | leukemia, |
| the results of the present study demonstrated that the miR-509-3p RCC suppressor was a significant regulator of the MAP3K8 oncogene, suggesting that it may have a potential therapeutic role in the treatment of renal cell carcinoma | kidney, |
| Study offers the characterization of oncogenic MAP3K8 alterations occurring exclusively in driver mutation-negative melanoma. It identifies six carboxy-terminal truncating MAP3K8 rearrangements in both primary and metastatic melanomas that were associated with decreased overall survival. Rearrangement and amplification of the MAP3K8 locus result in increased levels of a truncated but active MAP3K8 protein. | skin, |
| The proto-oncogene Cot kinase participates in CD3/CD28 induction of NF-kappaB acting through the NF-kappaB-inducing kinase and IkappaB kinases. | None |
| COT kinase proto-oncogene expression in T cells: implication of the JNK/SAPK signal transduction pathway in COT promoter activation. | None |
| Expression of the Tpl2/Cot oncogene in human T-cell neoplasias. | None |
| Deregulated activation of oncoprotein kinase Tpl2/Cot in HTLV-I-transformed T cells. | None |
| Tpl2, a potent oncogene, functions as a tumor suppressor gene in chronically stimulated T cells. | None |
| Results describe the proteomics analysis of immunoprecipitated proteins associated with the oncogenic kinase Cot. | None |
| Identification and characterization of protein products of the cot oncogene with serine kinase activity. | None |
| In vitro selection of adenine-dependent ribozyme against Tpl2/Cot oncogene. | None |
| Structure and transforming potential of the human cot oncogene encoding a putative protein kinase. | None |
| TPL2 was found to antagonize oncogene-induced cell transformation and survival through a pathway involving p53 downstream of cJun N-terminal kinase (JNK) and be required for optimal p53 response to genotoxic stress. | None |
| Identification of the cells expressing cot proto-oncogene mRNA. | None |
| The human cot proto-oncogene encodes two protein serine/threonine kinases with different transforming activities by alternative initiation of translation. | None |
| The murine cot proto-oncogene: genome structure and tissue-specific expression. | None |
| Activation of MEK-1 and SEK-1 by Tpl-2 proto-oncoprotein, a novel MAP kinase kinase kinase. | None |